The Journal of Immunology, 2000, 165: 4783-4786.
Copyright © 2000 by The American Association of Immunologists
Cutting Edge: Anti-CD154 Therapeutic Antibodies Induce Infectious Transplantation Tolerance1
Luis Graca2,3,
Karen Honey2,
Elizabeth Adams,
Stephen P. Cobbold and
Herman Waldmann
Sir William Dunn School of Pathology, Oxford, United Kingdom
 |
Abstract
|
|---|
Nondepleting anti-CD154 (CD40 ligand) mAbs have proven
effective in inducing transplantation tolerance in rodents and
primates. In the induction phase, anti-CD154 Ab therapy is known to
enhance apoptosis of Ag reactive T cells. However, this may not
be the sole explanation for tolerance, as we show in this study that
tolerance is maintained through a dominant regulatory mechanism which,
like tolerance induced with CD4 Abs, manifests as infectious tolerance.
Therefore, tolerance induced with anti-CD154 Abs involves not only
the deletion of potentially aggressive T cells, but also a contagious
spread of tolerance to new cohorts of graft-reactive T cells as they
arise.
 |
Introduction
|
|---|
The
Holy Grail of transplantation research has been to induce tolerance by
a short pulse of therapy. Long-term graft survival has been achieved in
rodents through the use of nondepleting mAbs such as anti-CD4 and
anti-CD154 (1, 2, 3, 4, 5, 6, 7). The potential of anti-CD154
therapy to produce prolonged graft survival even across a full MHC
mismatch in nonhuman primates (8, 9) has prompted an
analysis of mechanisms involved. Two elegant recent reports showed that
activation-induced cell death
(AICD)4 of potentially
aggressive T cells is an important feature of the induction phase of
the prolonged graft survival with CD154 Abs (10, 11). We
have previously shown that the CD4 T cell population in mice can indeed
be tolerized by CD154 Abs in circumstances where the
CD8+ population have been removed by prior Ab
ablation (5). In such circumstances we were able to
analyze the maintenance phase of tolerance and uncover a role for a
contagious process of tolerance (infectious tolerance). Infectious
tolerance has been observed by us following tolerance induction with
nondepleting CD4 mAb in skin and marrow transplants over multiple minor
histocompatibility barriers, and heart transplants across complete MHC
histocompatibility barriers (7). We show in this study
that tolerance, once it has been induced by CD154 Abs, cannot be broken
by the adoptive transfer of large numbers of naive nontolerant T cells.
When these naive cells are allowed to coexist with the regulatory
population for 6 wk, they become tolerant themselves, so exhibiting
infectious tolerance. These results lead us to conclude that tolerance
induced with CD154 Abs involves not just the deletion of alloreactive T
cells but also maintenance through a contagious spread of tolerance to
new graft-reactive T cells as they arise.
 |
Materials and Methods
|
|---|
Mice
CBA/Ca (H-2k), CD52-transgenic CP1-CBA/Ca
(H-2k), and B10.BR (H-2k)
mice were bred and maintained in the specific pathogen-free facilities
of the Sir William Dunn School of Pathology (Oxford, U.K.). All groups
were age and sex matched. All procedures were conducted in accordance
with the Home Office Animals (Scientific Procedures) Act of
1986.
Thymectomy and skin grafting
Mice were anesthetized with a mixture of 10 mg/ml Hypnodil and 2
µg/ml Sublimaze (Janssen, Tilburg, Netherlands). A dose according to
body weight (0.12 ml per 20 g) was injected i.p. Thymectomy was
conducted as described by Monaco et al. (12). In short, a
longitudinal incision was made on the anterior surface of the neck, and
the thymus was removed as two intact lobes by the application of
negative pressure through a glass tip inserted in the anterior
mediastinum. Skin grafting was conducted according to a modified
technique of Billingham et al. (13). Briefly, a full
thickness of tail skin (1 x 1 cm) was grafted on the lateral
flank, and rechallenge grafts were placed on the contralateral flank.
Grafts were observed on alternate days after the removal of the bandage
and considered rejected when no viable donor skin was present.
Statistical analysis of graft survival was made by the log rank method
(14).
Adoptive cell transfer
Cells were obtained from spleens of adult naive CBA/Ca mice. A
single cell suspension was obtained by passing the splenocytes through
a 70 µm cell strainer (Becton Dickinson, Oxford, U.K.) and the
erythrocytes were depleted by water lysis. Cells were counted with a
hemocytometer, diluted in PBS, and 50 x 106
were injected i.v. into the tail vein.
mAbs and cell depletion
CD8+ cell depletion in athymic mice was
achieved using a mixture of 1 mg YTS 156.7 (15) and 1 mg
YTS 169.4 (16) injected i.p. on days 1 and 0 with respect
to transplantation. For depletion of CP1-CBA T cells, 0.1 mg CAMPATH-1H
(17) was injected i.p. These mAbs, as well as MR1
(18), were produced in our laboratory by culture in hollow
fiber bioreactors, purified from culture supernatants by 50% ammonium
sulfate precipitation, and dialyzed against PBS, and the purity was
checked by native and SDS gel electrophoresis (PhastGel; Pharmacia, St.
Albans, U.K.).
Flow cytometric analysis
Peripheral blood samples were depleted of erythrocytes by water
lysis, washed, and resuspended in PBS, 1% w/v BSA, 5% v/v
heat-inactivated normal rabbit serum, and 0.1% w/v sodium azide. Cells
were incubated for 45 min at 4°C with directly conjugated
CAMPATH-1H-FITC, CD8
-PE (Sigma, Poole, U.K.), and CD4-CyChrome
(CyCr; PharMingen, San Diego, CA). The cells were washed, resuspended
in PBS, 1% w/v BSA, 0.1% w/v sodium azide, and fixed in 2% v/v
formaldehyde solution. Tricolor FACScan analysis (Becton Dickinson) was
performed using CellQuest (Becton Dickinson) software.
 |
Results and Discussion
|
|---|
We used CD8-depleted mice treated with CD154 Abs to produce
tolerance to B10.BR skin grafts which differ over multiple minor
histocompatibility Ags. This model has proven useful in previous
descriptions of infectious tolerance with CD4 Abs, and many parameters
of cell dose and potency in adoptive transfer studies have been well
characterized (19). Previous studies have demonstrated
that regulatory cells involved in CD4 Ab-induced transplantation
tolerance are themselves CD4+ (20).
We wished to be able to distinguish any such CD4+
regulatory T cells from naive CD4 T cells that could reject grafts.
Therefore, we used CBA/Ca mice, transgenic for the human CD52 gene
expressed under the control of the CD2 promoter, as the tolerized host,
and normal CBA/Ca mice as a source of naive nontolerant T cells for
adoptive transfer. It was thus possible to identify and specifically
deplete host T cells using the CD52 specific CAMPATH-1H mAb
(21). These transgenic mice, named CP1-CBA, are
histocompatible with CBA/Ca mice (confirmed by acceptance of reciprocal
skin grafts (data not shown)). Furthermore, when grafted with B10.BR
skin (differing by multiple minor histocompatibility Ags), both
transgenic and CBA/Ca strains rejected at a comparable rate (Fig. 1
A). To study infectious
tolerance we needed to be sure that once host T cells had been ablated
by the CAMPATH-1H Ab, they would not replenish from the thymus. For
that reason we used adult-thymectomized (ATx) CP1-CBA mice. Such ATx
mice depleted of T cells with 0.1 mg of CAMPATH-1H mAb accept B10.BR
skin grafts indefinitely (Fig. 1
A). Analysis of PBLs from
CAMPATH-1H treated mice by flow cytometry confirms that T cells are
depleted to <1% (Fig. 1
, B and C). This enabled
us to use the CAMPATH-1H mAb to ablate T cells of the tolerant
transgenic host whenever we wished, allowing us to determine the impact
of their prolonged coexistence with naive CBA/Ca T cells.

View larger version (20K):
[in this window]
[in a new window]
|
FIGURE 1. CP1-CBA reject B10.BR skin grafts at a similar rate to CBA/Ca, but not
after T cell depletion with CAMPATH-1H mAb. A, Adult
CP1-CBA ( , n = 4) mice reject B10.BR skin grafts
at a rate comparable with CBA/Ca ( , n = 8)
recipients. Adult ATx CP1-CBA donors treated with 0.1 mg CAMPATH-1H mAb
before B10.BR skin grafting permanently accept these grafts ( ,
n = 5, median survival time (MST) > 100
days). B, PBLs were analyzed by flow cytometry following
staining with CAMPATH-1H-FITC, CD8-PE, and CD4-CyCr. CP1-CBA mice T
cells are double positive for either CD4 or CD8 and CAMPATH-1H. It
should be noted that the CD8-CAMPATH-1H+ cells
in the upper panel are superimposed close to the horizontal axis and
can be seen as the CD4+ cells in the accompanying lower
plot. C, Euthymic CP1-CBA mice treated with 0.1 mg
CAMPATH-1H show depletion of both CD4+ and CD8+
T cells 7 days after treatment.
|
|
In this study, ATx, CD8+ cell-depleted CP1-CBA
were tolerized to B10.BR skin under the cover of three doses of the
nondepleting anti-CD154 mAb MR1, administered on days 0, 2, and 4
with respect to time of transplantation (5).
We investigated whether anti-CD154-induced tolerance was dominant
by testing whether the CP1-CBA mice tolerized to B10.BR skin as
described above could resist the adoptive transfer of spleen cells from
naive CBA/Ca mice (22). Ninety days after tolerance
induction, CP1-CBA-tolerant mice were injected i.v. with 50 x
106 spleen cells from naive CBA/Ca mice, and
received a fresh B10.BR skin graft the following day. The naive cells
did not break tolerance, as both the new and old skin grafts were
accepted indefinitely (Fig. 2
A). However, in control
groups in which mice received MR1 treatment in the absence of a first
skin graft, or where at the time of cell transfer, the host T cells had
been depleted with CAMPATH-1H Ab, B10.BR skin grafts were readily
rejected (Fig. 2
A). The levels of donor T cell chimerism and
host T cell depletion were analyzed by flow cytometry of PBLs (Fig. 2
B). These observations indicate that although naive T cells
did engraft, they were prevented from rejecting transplanted B10.BR
skin by tolerized host T cells.

View larger version (26K):
[in this window]
[in a new window]
|
FIGURE 2. Anti-CD154 treatment of CD8-depleted mice induces dominant tolerance
that is not broken by adoptive transfer of naive spleen cells.
A, Adult ATx and CD8 cell depleted CP1-CBA transgenic
mice received a B10.BR skin graft (multiple minor histocompatibility
differences) at day 90, with three doses of 0.67 mg of the nondepleting
anti-CD154 mAb MR1 i.p. at days 90, 88 and 86 to induce tolerance.
At day 0, mice from groups designated , , and received
50 x 106 spleen cells i.v. from naive CBA donors. All
mice received a fresh B10.BR skin graft the following day and were
monitored for graft rejection. Tolerant mice that received naive spleen
cells accepted the grafts indefinitely ( , n = 7,
MST > 100), as did tolerant mice receiving no naive cells ( ,
n = 6, MST > 100 days, p
< 0.28). The absence of rejection was not due to the persistence of
MR1 mAb as all animals in the control group that received the
tolerizing MR1 treatment in the absence of an initial skin graft
rejected the graft ( , n = 6, MST = 15
days). The transferred cells were competent to reject the B10.BR
skin, as mice depleted of their own T cells with 0.1 mg CAMPATH-1H
i.p. before cell transfer and skin grafting also rejected ( ,
n = 5, MST = 19 days). B, PBLs
were analyzed by flow cytometry following staining with
CAMPATH-1H-FITC, CD8-PE, and CD4-CyCr. Host lymphocytes, from CP1-CBA
transgenic mice, are CAMPATH-1H+. The CBA/Ca T cells that
were adoptively transferred were CAMPATH-1H-. Therefore,
it was possible to monitor the efficiency of cell transfer by flow
cytometry of the CD4 and CD8 populations of CAMPATH-1H-
cells. An example of a mouse from group is shown where 25% of
CD4+ and almost all of CD8+ T cells are from
the donor (the host had been CD8 depleted).
|
|
As dominant tolerance induced with CD4 Abs has been shown to involve
infectiousness (tolerant cells imposing tolerance on naive cells
(7, 20, 23)), we investigated whether infectious tolerance
had been induced by anti-CD154 therapy. Indicator CP1-CBA mice that
had been adult thymectomized and depleted of CD8+
T cells were tolerized to B10.BR skin grafts as above. After tolerance
had been confirmed by graft maintenance for 90 days, 50 x
106 spleen cells from naive CBA/Ca mice were
transferred i.v. into these tolerant mice, which then received a second
B10.BR skin graft the following day. This dose of spleen cells is well
in excess of the dose needed to get rapid graft rejection in this model
(19). When host cells were depleted with the CAMPATH-1H
mAb on the day following the adoptive transfer, the naive CBA/Ca cells
were fully competent to reject the new skin graft, as well as the
original one (Fig. 3
A).
However, if the naive CBA/Ca cells were allowed to coexist with the
tolerant cells for 6 wk, before depletion of host cells with CAMPATH-1H
mAb, and challenged with a third B10.BR skin graft on the day following
depletion, all three B10.BR skin grafts were accepted indefinitely
(Fig. 3
A). Flow cytometry confirmed donor T cell chimerism,
as well as effective host T cell depletion (Fig. 3
B).

View larger version (27K):
[in this window]
[in a new window]
|
FIGURE 3. Anti-CD154 treatment induces infectious transplantation tolerance.
A, Transplantation tolerance to B10.BR skin was induced
in ATx CP1-CBA transgenic mice with MR1 mAb as described before. Mice
from the group designated (n = 6) did not
receive naive cells. Spleen cells (50 x 106)
from naive CBA donors were adoptively transferred into the
animals of all other groups at day 0 (90 days after tolerance
induction), followed by a fresh B10.BR skin graft at day 1. In group
(n = 13), where host transgenic T cells were
depleted at day 1 with 0.1 mg CAMPATH-1H mAb i.p., both fresh and old
skin grafts were rejected (MST = 13 days). In group
(n = 5), the CBA lymphocytes were allowed to
coexist with the CP1-CBA cells for 6 wk, after which host T cells were
depleted with CAMPATH-1H and a further B10.BR skin was grafted
(MST > 150). There was no statistically significant difference in
graft survival for this group when compared with the groups that did
not receive naive CBA spleen cells ( , n = 6), or
in which the CP1-CBA cells were not depleted ( ,
n = 7). There is a significant difference between
the groups depleted at day 1 ( ) and day 45 ( ) after transfer
(p < 0.006). In animals receiving multiple
grafts, the most recent one was always the first to be lost and the one
considered in the analysis of data. B, PBLs were stained
with CAMPATH-1H-FITC, CD8-PE, and CD4-CyCr and analyzed by flow
cytometry, as before, to confirm the efficiency of depletion and cell
transfers. An example of a mouse from group , 45 days after
CAMPATH-1H depletion is shown, where the presence of
CAMPATH-1H- T cells of donor origin can be seen while the
host T cells are <1%.
|
|
Taken together with our previous findings of linked suppression in this
model of transplantation tolerance (5), these results
indicate that therapy with anti-CD154 in this context has a more
profound impact than can be explained just by deletion of potentially
aggressive T cells by AICD (10, 11). The notion of the
need for AICD arose from transplants across MHC barriers, and it is
conceivable that AICD may not be essential in tolerance across multiple
minor differences (24), although this remains to be
established. Equally, although infectious tolerance can be shown to
operate across MHC barriers when tolerance is induced with CD4 Abs, it
has not been formally demonstrated with CD154 Abs. Whether or not AICD
is operational in tolerance achieved across multiple minor differences,
we must conclude that a population of CD4+
regulatory T cells emerges from among the Ag-reactive T cells, and that
these are responsible for the maintenance phase of tolerance. They do
so not just by actively suppressing rejection, but also by imposing
tolerance on naive cells through infectious tolerance.
There are two possible mechanisms by which these regulatory cells may
arise. One (two-population model) is that these regulatory cells are
already present in the T cell pool as a distinct subpopulation. If they
were less susceptible to AICD than potentially aggressive cells they
would persist after anti-CD154 therapy and thus the ratio between
regulators and aggressors would be altered to favor tolerance. A
variant of this first model might require that AICD of the potentially
aggressive T cells permits the graft to survive long enough, for a
regulatory CD4+ cell population to expand and
then dominate. The other possible mechanism (single-population model)
is that potentially aggressive T cells which failed to die from AICD
might have changed function to become regulators as a consequence of
the Ag recognition in a tolerogenic environment. We cannot, at present,
distinguish between these two possibilities.
To exert infectious tolerance, such regulatory T cells would need to
influence naive T cells. This could be either by influencing the local
microenvironment of Ag presentation where both types of cells
(regulatory and naive) were in close proximity, or alternatively by
decommissioning APCs so that they presented to naive T cells for
tolerance rather than immunity.
 |
Footnotes
|
|---|
1 This work was supported by the Medical Research Council, the Wellcome Trust, and the European Community. L.G. is supported by the Calouste Gulbenkian Foundation Gulbenkian PhD Program in Biology and Medicine and the Portuguese Foundation for Science and Technology/Praxis XXI. 
2 L.G. and K.H. contributed equally to this study. 
3 Address correspondence and reprint requests to Dr. Luis Graca, Sir William Dunn School of Pathology, South Parks Road, Oxford, OX1 3RE, U.K. 
4 Abbreviations used in this paper: AICD, activation-induced cell death; ATx, adult-thymectomized; CyCr, CyChrome; MST, median survival time. 
Received for publication July 21, 2000.
Accepted for publication August 25, 2000.
 |
References
|
|---|
-
Qin, S. X., M. Wise, S. P. Cobbold, L. Leong, Y. C. Kong, J. R. Parnes, H. Waldmann. 1990. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur. J. Immunol. 20:2737.[Medline]
-
Parker, D. C., D. L. Greiner, N. E. Phillips, M. C. Appel, A. W. Steele, F. H. Durie, R. J. Noelle, J. P. Mordes, A. A. Rossini. 1995. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 92:9560.[Abstract/Free Full Text]
-
Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, et al 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434.[Medline]
-
Markees, T. G., N. E. Phillips, E. J. Gordon, R. J. Noelle, L. D. Shultz, J. P. Mordes, D. L. Greiner, A. A. Rossini. 1998. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4+ T cells, interferon-
, and CTLA4. J. Clin. Invest. 101:2446.[Medline]
-
Honey, K., S. P. Cobbold, H. Waldmann. 1999. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J. Immunol. 163:4805.[Abstract/Free Full Text]
-
Waldmann, H.. 1999. Transplantation tolerance: where do we stand?. Nat. Med. 5:1245.[Medline]
-
Waldmann, H., S. Cobbold. 1998. How do monoclonal antibodies induce tolerance: a role for infectious tolerance?. Annu. Rev. Immunol. 16:619.[Medline]
-
Kirk, A. D., L. C. Burkly, D. S. Batty, R. E. Baumgartner, J. D. Berning, K. Buchanan, Jr J. H. Fechner, R. L. Germond, R. L. Kampen, N. B. Patterson, et al 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5:686.[Medline]
-
Kenyon, N. S., M. Chatzipetrou, M. Masetti, A. Ranuncoli, M. Oliveira, J. L. Wagner, A. D. Kirk, D. M. Harlan, L. C. Burkly, C. Ricordi. 1999. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc. Natl. Acad. Sci. USA 96:8132.[Abstract/Free Full Text]
-
Li, Y., X. C. Li, X. X. Zheng, A. D. Wells, L. A. Turka, T. B. Strom. 1999. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5:1298.[Medline]
-
Wells, A. D., X. C. Li, Y. Li, M. C. Walsh, X. X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W. W. Hancock, et al 1999. Requirement for T cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5:1303.[Medline]
-
Monaco, A. P., M. L. Wood, J. G. Gray, P. S. Russell. 1966. Studies on heterologous anti-lymphocyte serum in mice. II. Effect on the immune response. J. Immunol. 96:229.[Abstract/Free Full Text]
-
Billingham, R. E., L. Brent, P. B. Medawar. 1953. Actively acquired tolerance to foreign cells. Nature 172:603.[Medline]
-
Peto, R., M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel, K. McPherson, J. Peto, P. G. Smith. 1977. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br. J. Cancer 35:1.[Medline]
-
Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature 312:548.[Medline]
-
Cobbold, S., H. Waldmann. 1986. Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets. Transplantation 41:634.[Medline]
-
Xia, M. Q., G. Hale, H. Waldmann. 1993. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol. Immunol. 30:1089.[Medline]
-
Noelle, R. J., M. Roy, D. M. Shepherd, I. Stamenkovic, J. A. Ledbetter, A. Aruffo. 1992. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA 89:6550.[Abstract/Free Full Text]
-
Davies, J. D., G. Martin, J. Phillips, S. E. Marshall, S. P. Cobbold, H. Waldmann. 1996. T cell regulation in adult transplantation tolerance. J. Immunol. 157:529.[Abstract]
-
Qin, S., S. P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, H. Waldmann. 1993. Infectious transplantation tolerance. Science 259:974.[Abstract]
-
Gilliland, L. K., L. A. Walsh, M. R. Frewin, M. P. Wise, M. Tone, G. Hale, D. Kioussis, H. Waldmann. 1999. Elimination of the immunogenicity of therapeutic antibodies. J. Immunol. 162:3663.[Abstract/Free Full Text]
-
Scully, R., S. Qin, S. Cobbold, H. Waldmann. 1994. Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. Eur. J. Immunol. 24:2383.[Medline]
-
Cobbold, S., H. Waldmann. 1998. Infectious tolerance. Curr. Opin. Immunol. 10:518.[Medline]
-
Li, X. C., M. S. Zand, Y. Li, X. X. Zheng, T. B. Strom. 1998. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J. Immunol. 161:2241.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
X. Huang, D. J. Moore, R. J. Ketchum, C. S. Nunemaker, B. Kovatchev, A. L. McCall, and K. L. Brayman
Resolving the Conundrum of Islet Transplantation by Linking Metabolic Dysregulation, Inflammation, and Immune Regulation
Endocr. Rev.,
August 1, 2008;
29(5):
603 - 630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, L. Ma, D. Yin, J. Shen, and A. S. Chong
Long-Term Control of Alloreactive B Cell Responses by the Suppression of T Cell Help
J. Immunol.,
May 1, 2008;
180(9):
6077 - 6084.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. B. Thornley, N. E. Phillips, B. C. Beaudette-Zlatanova, T. G. Markees, K. Bahl, M. A. Brehm, L. D. Shultz, E. A. Kurt-Jones, J. P. Mordes, R. M. Welsh, et al.
Type 1 IFN Mediates Cross-Talk between Innate and Adaptive Immunity That Abrogates Transplantation Tolerance
J. Immunol.,
November 15, 2007;
179(10):
6620 - 6629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Callaghan, F. J. Rouhani, M. C. Negus, A. J. Curry, E. M. Bolton, J. A. Bradley, and G. J. Pettigrew
Abrogation of Antibody-Mediated Allograft Rejection by Regulatory CD4 T Cells with Indirect Allospecificity
J. Immunol.,
February 15, 2007;
178(4):
2221 - 2228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Toda and C. A. Piccirillo
Development and function of naturally occurring CD4+CD25+ regulatory T cells
J. Leukoc. Biol.,
September 1, 2006;
80(3):
458 - 470.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhai, L. Meng, F. Gao, Y. Wang, R. W. Busuttil, and J. W. Kupiec-Weglinski
CD4+ T Regulatory Cell Induction and Function in Transplant Recipients after CD154 Blockade Is TLR4 Independent
J. Immunol.,
May 15, 2006;
176(10):
5988 - 5994.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Deng, D. J. Moore, X. Huang, M. Mohiuddin, M. K. Lee IV, E. Velidedeoglu, M.-M. Lian, M. Chiaccio, S. Sonawane, A. Orlin, et al.
Antibody-induced transplantation tolerance that is dependent on thymus-derived regulatory T cells.
J. Immunol.,
March 1, 2006;
176(5):
2799 - 2807.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. O. Salvalaggio, G. Camirand, C. E. Ariyan, S. Deng, L. Rogozinski, G. P. Basadonna, and D. M. Rothstein
Antigen Exposure during Enhanced CTLA-4 Expression Promotes Allograft Tolerance In Vivo
J. Immunol.,
February 15, 2006;
176(4):
2292 - 2298.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Nanji, W. W. Hancock, B. Luo, C. D. Schur, R. L. Pawlick, L. F. Zhu, C. C. Anderson, and A.M. J. Shapiro
Costimulation Blockade of Both Inducible Costimulator and CD40 Ligand Induces Dominant Tolerance to Islet Allografts and Prevents Spontaneous Autoimmune Diabetes in the NOD Mouse
Diabetes,
January 1, 2006;
55(1):
27 - 33.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Delgado, E. Gonzalez-Rey, and D. Ganea
The Neuropeptide Vasoactive Intestinal Peptide Generates Tolerogenic Dendritic Cells
J. Immunol.,
December 1, 2005;
175(11):
7311 - 7324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Krupnick, A. E. Gelman, W. Barchet, S. Richardson, F. H. Kreisel, L. A. Turka, M. Colonna, G. A. Patterson, and D. Kreisel
Cutting Edge: Murine Vascular Endothelium Activates and Induces the Generation of Allogeneic CD4+25+Foxp3+ Regulatory T Cells
J. Immunol.,
November 15, 2005;
175(10):
6265 - 6270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Quezada, K. Bennett, B. R. Blazar, A. Y. Rudensky, S. Sakaguchi, and R. J. Noelle
Analysis of the Underlying Cellular Mechanisms of Anti-CD154-Induced Graft Tolerance: The Interplay of Clonal Anergy and Immune Regulation
J. Immunol.,
July 15, 2005;
175(2):
771 - 779.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Lee, L. Wang, A. D. Wells, M. E. Dorf, E. Ozkaynak, and W. W. Hancock
Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor
J. Exp. Med.,
April 4, 2005;
201(7):
1037 - 1044.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Zhou, S. J. Balin, M. Mashayekhi, K. W. Hwang, D. A. Palucki, and M.-L. Alegre
Transplantation Tolerance in NF-{kappa}B-Impaired Mice Is Not Due to Regulation but Is Prevented by Transgenic Expression of Bcl-xL
J. Immunol.,
March 15, 2005;
174(6):
3447 - 3453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. H. Albert, X.-Z. Yu, P. J. Martin, and C. Anasetti
Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin
Blood,
February 1, 2005;
105(3):
1355 - 1361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Metzler, P. Gfeller, M. Bigaud, J. Li, G. Wieczorek, C. Heusser, P. Lake, and A. Katopodis
Combinations of Anti-LFA-1, Everolimus, Anti-CD40 Ligand, and Allogeneic Bone Marrow Induce Central Transplantation Tolerance through Hemopoietic Chimerism, Including Protection from Chronic Heart Allograft Rejection
J. Immunol.,
December 1, 2004;
173(11):
7025 - 7036.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Nagelkerken, I. Haspels, W. van Rijs, B. Blauw, J. L. Ferrant, D. M. Hess, E. A. Garber, F. R. Taylor, and L. C. Burkly
FcR Interactions Do Not Play a Major Role in Inhibition of Experimental Autoimmune Encephalomyelitis by Anti-CD154 Monoclonal Antibodies
J. Immunol.,
July 15, 2004;
173(2):
993 - 999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Vigouroux, E. Yvon, E. Biagi, and M. K. Brenner
Antigen-induced regulatory T cells
Blood,
July 1, 2004;
104(1):
26 - 33.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kurtz, J. Shaffer, A. Lie, N. Anosova, G. Benichou, and M. Sykes
Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells
Blood,
June 1, 2004;
103(11):
4336 - 4343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-C. Chen, S. P. Cobbold, P. J. Fairchild, and H. Waldmann
Generation of Anergic and Regulatory T Cells following Prolonged Exposure to a Harmless Antigen
J. Immunol.,
May 15, 2004;
172(10):
5900 - 5907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Cobbold, R. Castejon, E. Adams, D. Zelenika, L. Graca, S. Humm, and H. Waldmann
Induction of foxP3+ Regulatory T Cells in the Periphery of T Cell Receptor Transgenic Mice Tolerized to Transplants
J. Immunol.,
May 15, 2004;
172(10):
6003 - 6010.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. van Maurik, B. F. de St. Groth, K. J. Wood, and N. D. Jones
Dependency of Direct Pathway CD4+ T Cells on CD40-CD154 Costimulation Is Determined by Nature and Microenvironment of Primary Contact with Alloantigen
J. Immunol.,
February 15, 2004;
172(4):
2163 - 2170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Quezada, B. Fuller, L. Z. Jarvinen, M. Gonzalez, B. R. Blazar, A. Y. Rudensky, T. B. Strom, and R. J. Noelle
Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation
Blood,
September 1, 2003;
102(5):
1920 - 1926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. E. Phillips, T. G. Markees, J. P. Mordes, D. L. Greiner, and A. A. Rossini
Blockade of CD40-Mediated Signaling Is Sufficient for Inducing Islet But Not Skin Transplantation Tolerance
J. Immunol.,
March 15, 2003;
170(6):
3015 - 3023.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Mauri, D. Gray, N. Mushtaq, and M. Londei
Prevention of Arthritis by Interleukin 10-producing B Cells
J. Exp. Med.,
February 17, 2003;
197(4):
489 - 501.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. v. Maurik, M. Herber, K. J. Wood, and N. D. Jones
Cutting Edge: CD4+CD25+ Alloantigen-Specific Immunoregulatory Cells That Can Prevent CD8+ T Cell-Mediated Graft Rejection: Implications for Anti-CD154 Immunotherapy
J. Immunol.,
November 15, 2002;
169(10):
5401 - 5404.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Nicolls, M. Coulombe, J. Beilke, H. C. Gelhaus, and R. G. Gill
CD4-Dependent Generation of Dominant Transplantation Tolerance Induced by Simultaneous Perturbation of CD154 and LFA-1 Pathways
J. Immunol.,
November 1, 2002;
169(9):
4831 - 4839.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Graca, S. P. Cobbold, and H. Waldmann
Identification of Regulatory T Cells in Tolerated Allografts
J. Exp. Med.,
June 17, 2002;
195(12):
1641 - 1646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Graca, S. Thompson, C.-Y. Lin, E. Adams, S. P. Cobbold, and H. Waldmann
Both CD4+CD25+ and CD4+CD25- Regulatory Cells Mediate Dominant Transplantation Tolerance
J. Immunol.,
June 1, 2002;
168(11):
5558 - 5565.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Yamada, A. Chandraker, T. M. Laufer, A. J. Gerth, M. H. Sayegh, and H. Auchincloss Jr.
Cutting Edge: Recipient MHC Class II Expression Is Required to Achieve Long-Term Survival of Murine Cardiac Allografts After Costimulatory Blockade
J. Immunol.,
November 15, 2001;
167(10):
5522 - 5526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Pimenta-Araujo, L. Mascarell, M. Huesca, A. Cumano, and A. Bandeira
Embryonic Thymic Epithelium Naturally Devoid of APCs Is Acutely Rejected in the Absence of Indirect Recognition
J. Immunol.,
November 1, 2001;
167(9):
5034 - 5041.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gregori, M. Casorati, S. Amuchastegui, S. Smiroldo, A. M. Davalli, and L. Adorini
Regulatory T Cells Induced by 1{alpha},25-Dihydroxyvitamin D3 and Mycophenolate Mofetil Treatment Mediate Transplantation Tolerance
J. Immunol.,
August 15, 2001;
167(4):
1945 - 1953.
[Abstract]
[Full Text]
[PDF]
|
 |
|